Global Medical REIT Inc has a consensus price target of $10.69 based on the ratings of 6 analysts. The high is $12 issued by Alliance Global Partners on September 19, 2024. The low is $9 issued by BMO Capital on October 6, 2022. The 3 most-recent analyst ratings were released by Berenberg, Alliance Global Partners, and B. Riley Securities on October 18, 2024, September 19, 2024, and May 13, 2024, respectively. With an average price target of $11.25 between Berenberg, Alliance Global Partners, and B. Riley Securities, there's an implied 28.13% upside for Global Medical REIT Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Global Medical REIT (NYSE:GMRE) was reported by Berenberg on October 18, 2024. The analyst firm set a price target for $11.75 expecting GMRE to rise to within 12 months (a possible 33.83% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Global Medical REIT (NYSE:GMRE) was provided by Berenberg, and Global Medical REIT initiated their buy rating.
There is no last upgrade for Global Medical REIT
The last downgrade for Global Medical REIT Inc happened on October 10, 2022 when Baird changed their price target from N/A to N/A for Global Medical REIT Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Global Medical REIT, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Global Medical REIT was filed on October 18, 2024 so you should expect the next rating to be made available sometime around October 18, 2025.
While ratings are subjective and will change, the latest Global Medical REIT (GMRE) rating was a initiated with a price target of $0.00 to $11.75. The current price Global Medical REIT (GMRE) is trading at is $8.78, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.